Electronic nicotine delivery systems: emerging science foundation for policy

  title={Electronic nicotine delivery systems: emerging science foundation for policy},
  author={Jack E. Henningfield and Ghazi S. Zaatari},
  journal={Tobacco Control},
  pages={89 - 90}
Since they were first marketed in China in 2004, electronic nicotine delivery systems (ENDS) have spread globally like wildfire. Their proponents, who refer to the products as “electronic cigarettes” or “E-cigs”, argue that by delivering nicotine to the lung, they are more effective and acceptable than nicotine replacement medicines, and should be readily available as cigarette substitutes. An internet search using terms such as “electronic cigarette” reveals that the products vary widely in… Expand
Electronic nicotine delivery systems: a research agenda
The authors, who cover a broad range of scientific expertise, from basic science to public health, suggest research priorities for non-clinical, clinical and public health studies, and conclude that the first priority is to characterize the safety profile of these products, including in long-term users. Expand
Electronic Nicotine Delivery Systems (“E-cigarettes”)
Clinicians are advised to be aware that the use of e-cigarettes, especially among cigarette smokers, is growing rapidly and these devices are unregulated, of unknown safety, and of uncertain benefit in quitting smoking. Expand
Novel nicotine delivery systems and public health: the rise of the "e-cigarette".
These devices pose significant challenges to the public health community because their distribution and use has become widespread in the United States while simultaneously evading most regulatory structures and force a close consideration of how the health and regulatory system evaluates claims of safety and harm reduction in a dynamic, consumer driven environment to ensure the broad protection of public health. Expand
Position statement on electronic cigarettes or electronic nicotine delivery systems.
  • T. Bam, W. Bellew, +7 authors M. Wisotzky
  • Medicine
  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2014
The International Union Against Tuberculosis and Lung Disease strongly supports the regulation of the manufacture, marketing and sale of electronic cigarettes or ENDS; the preferred option is to regulate ECs orENDS as medicines. Expand
NIH electronic cigarette workshop: developing a research agenda.
This paper describes proceedings from a National Institutes of Health-sponsored workshop, which was held in November 2013, to identify research needs related to the effects of e-cigarettes, and identifies the research needs identified by participants. Expand
Science and Electronic Cigarettes: Current Data, Future Needs
The available research on what ECIGs are, effects of use, survey data on awareness and use, and the utility ofECIGs to help smokers quit using tobacco cigarettes are described. Expand
E-Cigarettes: A Rapidly Growing Internet Phenomenon
Physicians should be aware of the popularity, questionable efficacy claims, and safety concerns of e-cigarettes so that they may counsel patients against use and advocate for research to inform an evidence-based regulatory approach. Expand
Nicotine levels in electronic cigarettes 3 Nicotine & Tobacco Research
small kiosks in shopping malls. ECs were developed in 2004 in China, who remains the main manufacturer of these devices. ECs have not been manufactured by any tobacco or pharmaceutical companies andExpand
Electronic nicotine delivery systems: regulatory and safety challenges: Singapore perspective
The results show poor consistency between actual nicotine content analysed on ENDS cartridges and the amount labelled, which raises safety and efficacy concerns for current and would-be recreational users or those trying to quit smoking. Expand
Electronic nicotine delivery systems: adult use and awareness of the ‘e-cigarette’ in the USA
Given the large increase in awareness and ever use of ENDS during this 1-year period and the unknown impact of EN DS use on cigarette smoking behaviours and long-term health, continued monitoring of these products is needed. Expand


Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation.
The present review does not address whether particle size regulation would be a plausible means of substantially reducing addictiveness or harmfulness of cigarettes, and therefore it is not proposed as a high-priority target for regulation. Expand
Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study
The use of e-Cigarette substantially decreased cigarette consumption without causing significant side effects in smokers not intending to quit, and perception and acceptance of the product was good. Expand
Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial
The 16 mg Ruyan V8 ENDD alleviated desire to smoke after overnight abstinence, was well tolerated and had a pharmacokinetic profile more like the Nicorette inhalator than a tobacco cigarette. Expand
Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.
Developments include understanding the population-based and individual differences in the vulnerability to dependence and responsiveness to various treatment options, which could contribute to effective treatment to patient matching as well as the challenges to medication development. Expand
Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products
The traditional tools and methods of ALA that can be used to evaluate new tobacco and nicotine products including MRTP/PREPs are described, which could contribute to the scientific foundation on which future public policy decisions are based. Expand
The reemergence of smokeless tobacco.
Policy makers are taking the opportunity to intervene with preventive measures to protect a new generation of tobacco users from the effects of smokeless tobacco. Expand
Site of nicotine absorption from a vapour inhaler – comparison with cigarette smoking
Nicotine absorption after use of the vapour inhaler occurs primarily via the mucosa of the oral cavity; the absorption occurs slowly and the arterial nicotine concentration spike, typical of cigarette smoking, is avoided. Expand
Electronic cigarettes: safety concerns and regulatory issues.
  • Kristine A Wollscheid, Mary E Kremzner
  • Business, Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2009
The wide availability and aggressive marketing of these products may leave health care providers and patients asking an important public health question. Expand
Evaluation of Indoor Air Sampling Near Philip Services Corporation, Seattle, Health Consultation
+ Kristina M. Adams, MS Technical Information Specialist Animal Welfare Information Center (AWIC) USDA, National Agricultural Library 10301 Baltimore Avenue, Room 118-J Baltimore, MD 20705-2351 +Expand
E Cigarette") on desire to smoke and withdrawal, user preferences and nicotine delivery: randomized cross-over trial
  • Tob Control
  • 2010